300529.SHE Jafron Biomedical Co Ltd
- Market cap
- CNY 15.1B
- P/E
- 22.5x
- P/B
- 3.87x
- ROE
- 21.0%
- Dividend yield
- 4.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300529.SHE undervalued?
Graham number300529.SHE trades 96.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jafron Biomedical Co Ltd fundamental analysis
No fundamental analysis for Jafron Biomedical Co Ltd yet.
Jafron Biomedical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialy…
Full company profileJafron Biomedical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jafron Biomedical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 544M | 718M | 1.02B | 1.43B | 1.95B | 2.68B | 2.49B | 1.92B | 2.68B | 2.01B | 2.15B |
| Gross Profit | 456M | 605M | 862M | 1.23B | 1.66B | 2.27B | 2.05B | 1.53B | 2.16B | 1.58B | 1.69B |
| Operating Income | 233M | 332M | 476M | 680M | 1.05B | 1.42B | 1.03B | 544M | 1.05B | 740M | 942M |
| EBITDA | 240M | 311M | 431M | 634M | 1.00B | 1.37B | 996M | 573M | 1.12B | 836M | 951M |
| Net Income | 202M | 284M | 402M | 571M | 875M | 1.20B | 890M | 436M | 820M | 533M | 766M |
| EPS | 0.27 | 0.36 | 0.51 | 0.72 | 1.08 | 1.49 | 1.11 | 0.55 | 1.07 | 0.67 | 0.96 |
| Balance Sheet | |||||||||||
| Total Assets | 1.30B | 1.70B | 2.05B | 2.49B | 3.22B | 4.81B | 5.41B | 5.54B | 5.38B | 5.41B | 5.51B |
| Total Liabilities | 116M | 311M | 330M | 324M | 383M | 1.43B | 1.82B | 2.39B | 2.05B | 1.94B | 1.85B |
| Shareholders' Equity | 1.18B | 1.39B | 1.70B | 2.14B | 2.81B | 3.36B | 3.57B | 3.15B | 3.33B | 3.47B | 3.65B |
| Cash & Short-term Investments | 760M | 1.06B | 1.08B | 1.27B | 1.58B | 2.47B | 2.56B | 2.81B | 2.32B | 2.52B | 855M |
| Total Debt | - | 137M | 107M | 59.7M | 30.2M | 918M | 1.28B | 1.65B | 1.19B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 179M | 304M | 384M | 583M | 957M | 1.25B | 884M | 917M | 1.05B | 721M | - |
| Capital Expenditure | 28.7M | 178M | 174M | 221M | 357M | 537M | 476M | 247M | 235M | 173M | 167M |
| Free Cash Flow | 150M | 126M | 211M | 363M | 600M | 712M | 408M | 669M | 816M | 549M | 819M |
| Ratios | |||||||||||
| ROE | 17.1% | 20.4% | 23.7% | 26.6% | 31.2% | 35.6% | 24.9% | 13.9% | 24.6% | 15.3% | 21.0% |
| ROA | 15.5% | 16.7% | 19.6% | 22.9% | 27.2% | 24.9% | 16.4% | 7.9% | 15.2% | 9.9% | 13.9% |
| Net Profit Margin | 37.2% | 39.6% | 39.5% | 39.9% | 44.9% | 44.7% | 35.7% | 22.7% | 30.6% | 26.5% | 35.7% |
| Debt to Equity | - | 0.10x | 0.06x | 0.03x | 0.01x | 0.27x | 0.36x | 0.53x | 0.36x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jafron Biomedical Co Ltd dividends
- Dividend yield
- 4.27%
- Forward dividend
- 0.52 CNY
- Payout ratio
- 120.8%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 644M | 0.81 | 120.8% |
| 2024 | CNY 340M | 0.44 | 41.5% |
| 2023 | CNY 562M | 0.71 | 128.7% |
| 2022 | CNY 717M | 0.90 | 80.6% |
| 2021 | CNY 531M | 0.66 | 44.4% |
| 2020 | CNY 378M | 0.47 | 43.2% |
| 2019 | CNY 251M | 0.32 | 44.0% |
| 2018 | CNY 146M | 0.19 | 36.4% |
| 2017 | CNY 83.3M | 0.11 | 29.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.9:1 on May 20, 2020.
Who owns Jafron Biomedical Co Ltd
- Insiders 50.39%
- Institutions 4.67%
- Public & others 44.94%
- Shares outstanding 799M
- Free float 375M
Jafron Biomedical Co Ltd company profile
- Company name
- Jafron Biomedical Co Ltd
- Ticker
- 300529.SHE
- ISIN
- CNE100002995
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,301
- Fiscal year end
- December
- Address
- No. 98 Technology Six Road, Zhuhai, China, 519085
- Phone
- 86 75 6368 9708
- Website
- jafroninternational.com
About Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Jafron Biomedical Co Ltd management
8- Mr. Fan DongChairman of Board of Directors & GM · born 1970
- Ms. Xueyun LiaoDirector & Financial Director · born 1977
- Mr. De Zhi LiVice President · born 1966
- Ms. Xian Min TangVP & Director · born 1970
- Mr. Feng LiVP & Non-Independent Director · born 1970
- Mr. Aijun WuVice President · born 1965
- Mr. Rui WangGeneral Manager · born 1962
- Ms. Cong HuangBoard Secretary · born 1992